Harvard Business Review

SEPTEMBER 15, 2014

As Linda Hill and her colleagues have described, the company needed expert knowledge as it navigated the technically and ethically challenging waters of pharmaceutical development and marketing. In 2008, Pfizer was struggling with an unwieldy and costly model of obtaining outside legal help.

Gilbert 13

Gilbert Participative Cooper Network Economy 13

Harvard Business Review

MARCH 24, 2011

Competitors whispered that Gupta was committing the most un-McKinsey-like of sins: cutting price to get into new markets. As the stock market began to take off, though, and options rained down on corporate execs, the compensation tables began to turn, certainly for the top ranks.

McKinsey 16

McKinsey Consultative Waterman Intellectual Capital 16

Harvard Business Review

NOVEMBER 28, 2017

One of your executives comes to you with a proposal: she wants to lower the quality of service at the restaurants, reduce product safety standards, use deceptive marketing practices, lower employee pay, and adopt worse environmental practices. Why do anti-profit beliefs persist in a market society? Our research.

Company 8

Company Short-term Long-term Price 8

Harvard Business Review

APRIL 15, 2015

million industrial robots are in use or available in various industries including automotive, electronics, rubber and plastics, cosmetics, pharmaceutical, and food and beverage. Their market value is $9.5 Imagine: Future robots could be built to include a kind of ethical clause that limits what they are allowed to do.

Definition 8

Definition Ethics Industry Automotive 8

Harvard Business Review

JANUARY 10, 2013

initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. The most notable was Fannie Mae's $10.8 billion restatement. In another instance, a new enforcement. The largest payments were from Pfizer ($2.3 billion) and GlaxoSmithKline ($3 billion).

Finance 12

Finance Banking Press Release Pharmaceuticals 12

Harvard Business Review

SEPTEMBER 19, 2016

This logic and the institutions that reinforce it, like competitive markets and the rule of law, have transformed the world and lifted billions of people from poverty. Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. How should you make this decision?

ROI 8

ROI Long-term Conflict of Interest Pharmaceuticals 8

Marshall Goldsmith

FEBRUARY 8, 2018

Deepa Prahalad – Focused on design and emerging markets. Telisa Yancy – Chief Marketing Officer at American Family Insurance. Former HR director with Pepsi Central Eastern Europe, and gained HR expertise at PLIVA Pharmaceutical Company (now part of Teva Group). World authority on project management. Non-profit CEOs.

Executive Coaching 70

Executive Coaching CEO Banking Magazine 70

HR Digest

FEBRUARY 22, 2025

Statistics: AIHRs 2025 forecast notes that 60% of companies using ATS report a 25% faster time-to-hire, a lifeline in Californias competitive job market. Example: A recommendation from your HRIS to promote a Houston coder or upskill a Dallas pharmaceutical representative. You won’t know unless you track the data.

Compliance 52

Compliance Human Resources Trends Software 52

Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. At Harvard's Edmond J. But why not?

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. Experimentation is vital.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

NOVEMBER 5, 2015

As a child I felt no particular interest in pharmaceuticals, telecommunications, computers, oil and gas, health and beauty aids, medical devices, airlines, or shipbuilding, all of which I’ve simulated or war-gamed. I wonder what makes people market products that they know cause addiction and death. Then they grow up.

Career 8

Career Seminar Self-aware Telecommunications 8

Harvard Business Review

FEBRUARY 3, 2017

The business model of research-based pharmaceutical companies is under significant pressure. This strategy will tap potential growth in emerging markets, limit the risks of misconduct, and improve public trust in the industry. However, it also reflects stronger pressures to lower medicine costs in traditional pharmaceutical markets.

Reputation 8

Reputation Pharmaceuticals Price Business Model 8